Referencias
1. Molero Y, Larsson H, D'Onofrio BM, Sharp DJ, Fazel S. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. BMJ. 2019;365:l2147. DOI: 10.1136/bmj.l2147.
2. Ficha técnica de pregabalina. Disponible en: https://www.ema.europa.eu/en/documents/product-information/lyrica-epar-product-information_es.pdf
3. Ficha técnica de gabapentina. Disponible en: https://cima.aemps.es/cima/dochtml/ft/68172/FichaTecnica_68172.html
4. Spence D. Bad medicine: gabapentin and pregabalin. BMJ. 2013;347:f6747. DOI: 10.1136/bmj.f6747.
5. Goodman CW, Brett AS. A Clinical Overview of Off-label Use of Gabapentinoid Drugs. JAMA Intern Med. 2019;179(5):695-701. DOI: 10.1001/jamainternmed.2019.0086.
6. Mathieson S, Maher CG, McLachlan AJ, Latimer J, Koes BW, Hancock MJ, et al. Trial of pregabalin for acute and chronic sciatica. N Engl J Med. 2017;376(12):1111-20. DOI: 10.1056/NEJMoa1614292.